Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Clinical Pharmacology
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Clinical Pharmacology
    FDA Approves Aripiprazole to Treat Irritability Associated With Autistic Disorder - (DGNews)
    Pretreatment With Enoxaparin, Fondaparinux Improves Survival in Patients With Acute MI Awaiting PCI: Presented at AHA - (DGDispatch)
    Statins Can Reduce Risk of Major Cardiovascular Events in Healthy Women: Presented at AHA - (DGDispatch)
    Long-Term Data Confirm Findings of Heart Attack Prevention Trial: Presented at AHA - (DGDispatch)
    Concern About Risks May Not Deter Men From Purchasing Prescription-Only Medications Without a Prescription: Presented at ESSM - (DGDispatch)

    News archive

     Recent webcasts/CME - Clinical Pharmacology
    • Optimizing Insulin-Dependent Diabetes Management in Long-Term Care
    • Evolving Strategies for Chronic Idiopathic Thrombocytepenic Purpura
      Advances in the Treatment of NHL: Updates from the 2009 Pan Pacific Lymphoma Conference
      Fibromyalgia: The Patient Who Hurts Too Much
      Patient-Centered Approaches to the Evaluation and Management of Atrial Fibrillation

      Webcasts/CME archive

       Recent cases - Clinical Pharmacology
        Persistent Orocutaneous and Anal Fistulae Induced by Nicorandil: A Case Report
        Successful Use of Single-Dose Rituximab for the Maintenance of Remission in a Patient with Steroid-Resistant Nephrotic Syndrome
        Recurrent Stupor Associated with Chronic Valproic Acid Therapy and Hyperammonemia
        A Fatal Case of Ceftriaxone-Induced Autoimmune Hemolytic Anemia
        Clinical Considerations Regarding ß-Blocker Use in Patients with Reactive Airway Disease: A Report of 3 Cases

        Cases archive
          




        my personal edition > clinical pharmacology > news
        divider

          E-Mail this DGNews to a colleague

        DGNews


        Vasopressin-Receptor Antagonists May Help Treat Wide Range of Conditions

        NEW YORK -- May 9, 2008 -- A study appearing in the May 10, 2008, issue of The Lancet suggests that a new class of drugs called vasopressin-receptor antagonists, or vaptans, may be used to treat a wide range of conditions, including dysmenorrhoea, brain haemorrhage, psychotic disorders, and glaucoma.

        In the article, Professor Guy Decaux, Erasmus University Hospital, Brussels, Belgium, and colleagues noted that vaptans can be taken orally or intravenously and work by competing with vasopressin hormone molecules for the same receptor "active sites" on cells, thus blocking the action of vasopressin.

        Various subclasses of vaptan have been developed or are in development. Relcovaptan has shown initial positive results in the treatment of dysmenorrhoea, Raynaud's disease, and tocolysis.

        A second subclass of vaptans, which target a different cell receptor site, include mozavaptan, lixivaptan, satavaptan, and tolvaptan. These drugs induce diuresis without the loss of mineral salts from the body that accompanies the use of other diuretics. This class of vaptans can be used to treat hyponatraemia. Conivaptan is the only vaptan currently approved by the US Food and Drug Administration for the treatment of hyponatraemia. Drugs in this class are in development to treat a number of conditions, including renal failure related to polycystic kidney disease, diabetic nephropathy, cirrhosis, and depression.

        There also have been promising preliminary studies of vaptans for the treatment of glaucoma, Meniere's disease, brain haemorrhage, and small-cell cancer.

        SOURCE: The Lancet



        E-Mail this DGNews to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send